Lexaria Files New Patent Application for Enhanced Transdermal Delivery System

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce it has filed a new patent application with the United States Patent and Trademark Office ("USPTO") for use of DehydraTECHTM to improve the speed and quantity of absorption of active pharmaceutical ingredients ("API") through the skin.

Lexaria Enters Licensing Agreement with Canadian Cannabis Chocolate Manufacturer

Lexaria Bioscience Corp. (OTCQX: LXRP) (CNSX: LXX) (the "Company" or "Lexaria") a drug delivery platform innovator, announces it has entered a definitive technology licensing agreement (the "Agreement") with Cannfections Group Inc. whereby Lexaria is providing its patented DehydraTECH™ technology to empower next-generation performance in cannabis infused chocolates and candies to be developed and sold in Canada and internationally.

Lexaria Bioscience Files S4 Prospectus to Re-Domicile To Canada

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the ''Company'' or ''Lexaria'') announces that, on January 5, 2018, it filed a registration statement and shareholder information circular on Form S-4 with the US Securities and Exchange Commission (the ''SEC'') pursuant to which Lexaria will seek shareholder approval to change its corporate domicile from the State of Nevada to the Province of British Columbia, Canada, home of Lexaria's operations and management.

Lexaria Bioscience Announces New Research Including Cannabinoid Topical Creams and Nicotine Edibles

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX), a drug delivery platform innovator, announces a new topical skin cream research and development program; R&D into nicotine edibles; and updates existing R&D programs.

Topical Skin Formulations for Cannabinoids.

Lexaria Bioscience Files Innovative New Patent Application

Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) a drug delivery platform innovator, announces it has filed a new patent application with the US Patent and Trademark Office utilizing the Lexaria DehydraTECHTM technology for delivery of phosphodiesterase type 5 (PDE5) inhibitors - trade names of existing well-known products include ViagraTM (sildenafil) and CialisTM  (tadalafil).

Pages